MHC tailored for diabetes cell therapy

Gene Therapy

Volumn 12, Issue 7, 2005, Pages 553-554

  Trucco, M ^a   Giannoukakis, N ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AUTOANTIGEN; CYCLOPHOSPHAMIDE; HLA DQ ANTIGEN; HLA DQ8 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE IMMUNOTHERAPY; ALLELE; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BETA CHAIN; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC SUSCEPTIBILITY; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TRANSGENE; ANIMAL; GENE; GENETICS; METHODOLOGY; MOUSE; NONOBESE DIABETIC MOUSE;

ANIMALS; DIABETES MELLITUS, TYPE 1; GENE THERAPY; GENES, MHC CLASS II; HUMANS; MICE; MICE, INBRED NOD;

EID: 16344389886     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302431     Document Type: Note

References (10)

1. Tian C et al. J Clin Invest 2004; 114: 969-978.
2. McDevitt HO. N Engl J Med 2001; 345: 1060-1061.
3. Lee KH, Wucherpfenning KW, Wiley DC. Nat Immunol 2001; 2: 501-507.
4. Acha-Orbea H, McDevitt HO. Proc Natl Acad Sci USA 1987; 84: 2435-2438.
5. Lund T et al. Nature 1990; 345: 727-729.
6. Kaufman CL, Li H, Ildstad ST. J Immunol 1997; 158 2435-2442.
7. Andre-Schmutz I, Hindelang C, Benoist C, Mathis D. Eur J Immunol 1999; 29: 245-255.
8. Pietropaolo M et al. Diabetologia 2002; 45: 66-71.
9. Haviernik P, Bunting KD. Curr Gene Ther 2004; 4: 263-276.
10. Zorina T et al. Stem Cells 2003; 21: 377-388.